Patent SG-11201807148R-A (SG)
Title: Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions
Inventor: DRUMMOND DARYL C
IPC: A61K47/69
Filed: 2017-03-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 September 2017 (21.09.2017) WIPO I PCT (10) International Publication Number WO 2017/161067 Al 111111111111110111010101111101011111011101111111101011011001111111111111110111111 (51) International Patent Classification: A61K 47/69 (2017.01) (21) International Application Number: PCT/US2017/022624 (22) International Filing Date: 16 March 2017 (16.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/309,222 16 March 2016 (16.03.2016) US 62/322,940 15 April 2016 (15.04.2016) US 62/338,052 18 May 2016 (18.05.2016) US 62/419,012 8 November 2016 (08.11.2016) US 62/464,538 28 February 2017 (28.02.2017) US (71) Applicant: MERRIMACK PHARMACEUTICALS, INC [US/US]; One Kendall Square, Suite B7201, Cam- bridge, Massachusetts 02139 (US). (72) Inventors: DRUMMOND, Daryl C.; 1 Brooks Road, Lin- coln, Massachusetts 01773 (US). KIRPOTIN, Dmitri B.; 382 Ocean Avenue, Apt. 1509, Revere, Massachusetts 02151 (US). HUANG, Zhaohua R.; 2115 Washington Street, Braintree, Massachusetts 02184 (US). TIPPAR- AJU, Suresh K.; 48 Epping Street, Arlington, Massachu- setts 02474 (US). NOBLE, Charles; 990 Carolina St, San Francisco, California 94158 (US). (74) Agent: DAY, Noel E.; Honigman Miller Schwartz & Cohn LLP, 350 East Michigan Avenue, Suite 300, Kalamazoo, Michigan 49007 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 16 1067 Al (54) Title: EPHRIN RECEPTOR A2 (EPHA2)-TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSI- TIONS (57) : EphA2-targeted immunoliposomes for delivering docetaxel are useful in the treatment of certain types of cancer. The immunoliposomes can include an EphA2 targeting moiety (e.g., a scFv) and encapsulate a docetaxel prodrug in a stable salt form within a liposome having an average size of about 100 nm. Novel docetaxel prodrugs suitable for loading into nanoliposomes (in - cluding immunoliposomes) are provided, along with novel and other useful EphA2 targeting moieties for preparation of EphA2-tar - geted doxorubicin-generating immunoliposome therapies. Pharmaceutical compositions can be prepared that include nanoliposomes encapsulating one or more docetaxel prodrugs, and/or immunoliposomes or nanoparticles comprising an EphA2 binding moiety and encapsulating one or more docetaxel prodrugs. The pharmaceutical compositions are useful for administration to a patient for the treatment of cancer.